Agilent bags FDA nod for key cancer diagnostic

The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen

Bristol Myers Squibb’s Camzyos shows breakthrough results in adolescents with obstructive hypertrophic cardiomyopathy

The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract

Shreehas Tambe appointed CEO & Managing Director of Biocon

Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited

Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal

Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones

MGM Healthcare builds world’s largest intestinal transplant program in 3 years

Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone

Quality Care India partners Intuitive to take robotic surgery beyond metros

Nova IVF Fertility expands in Kerala with acquisition of Craft Fertility

The timing of the partnership is crucial, as Kerala’s fertility rate has dropped to approximately 1.35–1.7 children per woman, below the replacement level of 2.1

Japan okays new long-acting eye drug

It promises fewer injections for vision loss patients

Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer

The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival

Pfizer reports breakthrough in advanced prostate cancer with TALZENNA Plus XTANDI

The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI